Mortality rate and survivability of cats diagnosed with chronic kidney disease and the effectiveness of telmisartan in management of proteinuria

Chronic kidney disease (CKD) is commonly diagnosed in cats; especially in geriatric patients. Early management of CKD patients is up most important in order to slow down the disease progression. Management of feline CKD includes controlling proteinuria, maintaining the level of serum creatinine, inorganic phosphate level, and hypertension (if present). Greater level of proteinuria has been associated with faster progression of the kidney disease in humans and similarly in dogs and cats. A study conducted proven that telmisartan can help to reduce the degree of proteinuria in feline CKD patients. Thus the objectives of this study were; 1) to determine the mortality rate and survivability of cats diagnosed with chronic kidney disease; and 2) to determine the effectiveness of telmisartan on controlling proteinuria, blood pressure and serum creatinine level in cats diagnosed with CKD. Feline cats patients from year January 2016 to December 2017 diagnosed with chronic kidney disease were reviewed and owners were contacted for follow-up of the patient condition. Based on the information obtained, each cat patient’s kidney condition were staged, the mortality rate and estimated survivability rate were calculated. Five client-owned cats (stable CKD patients with supportive subcutaneous fluid therapy and renal supplement) were recruited for treatment with telmisartan. Baseline serum creatinine level, arterial blood pressure measurement and urine protein to creatinine ratio (UP/C) were obtained and assessed again on Day-14, -30 and -60 of post telmisartan therapy. The data will be analyzed using One-way ANOVA to compare the effect of telmisartan on proteinuria, blood pressure and serum creatinine level. Results and Conclusions This study revealed the mortality rate of cats diagnosed with CKD from year 2016 to 2017 in UVH is 81.1%. We also found out that there is no significant association between owner compliance and survivability of CKD patients in this study. In this preliminary study, telmisartan shown beneficial effects in reducing proteinuria and systolic blood pressure in feline CKD patients.

Preview Text FPV 2018 34 IR.pdf Download (1MB) | Preview

Actions (login required)

View Item